This review examines the role of angiogenesis in breast cancer and its impact on drug resistance. Angiogenesis, the formation of abnormal blood vessels from existing capillaries or postcapillary venules, plays a critical role in tumor growth and development of resistance to breast cancer treatments. The review discusses how angiogenesis exacerbates tumor hypoxia, reduces effective drug concentrations within tumors, and alters the immune system, leading to drug resistance. Antiangiogenic therapy, which promotes tumor vascular normalization, has emerged as a promising approach to overcome drug resistance. The combination of antiangiogenic therapy with chemotherapy, targeted therapy, or immunotherapy is explored as a potential strategy to enhance treatment efficacy. The review also provides a comprehensive summary of specific antiangiogenic drugs and their effectiveness in reversing drug resistance in breast cancer. Additionally, it highlights the potential mechanisms underlying these interventions and the prospects for clinical application. Challenges and future directions in the use of antiangiogenic therapy are also discussed.This review examines the role of angiogenesis in breast cancer and its impact on drug resistance. Angiogenesis, the formation of abnormal blood vessels from existing capillaries or postcapillary venules, plays a critical role in tumor growth and development of resistance to breast cancer treatments. The review discusses how angiogenesis exacerbates tumor hypoxia, reduces effective drug concentrations within tumors, and alters the immune system, leading to drug resistance. Antiangiogenic therapy, which promotes tumor vascular normalization, has emerged as a promising approach to overcome drug resistance. The combination of antiangiogenic therapy with chemotherapy, targeted therapy, or immunotherapy is explored as a potential strategy to enhance treatment efficacy. The review also provides a comprehensive summary of specific antiangiogenic drugs and their effectiveness in reversing drug resistance in breast cancer. Additionally, it highlights the potential mechanisms underlying these interventions and the prospects for clinical application. Challenges and future directions in the use of antiangiogenic therapy are also discussed.